Does the media prefer PRQR or TCRX?

In the previous week, ProQR Therapeutics had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for ProQR Therapeutics and 1 mentions for TScan Therapeutics. ProQR Therapeutics' average media sentiment score of 0.51 beat TScan Therapeutics' score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PLX or TCRX?

In the previous week, Protalix BioTherapeutics and Protalix BioTherapeutics both had 1 articles in the media. Protalix BioTherapeutics' average media sentiment score of 1.49 beat TScan Therapeutics' score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DTIL or TCRX?

In the previous week, Precision BioSciences had 18 more articles in the media than TScan Therapeutics. MarketBeat recorded 19 mentions for Precision BioSciences and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 0.00 beat Precision BioSciences' score of -0.16 indicating that TScan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TCRX or VYGR?

In the previous week, Voyager Therapeutics had 6 more articles in the media than TScan Therapeutics. MarketBeat recorded 7 mentions for Voyager Therapeutics and 1 mentions for TScan Therapeutics. Voyager Therapeutics' average media sentiment score of 0.14 beat TScan Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Voyager Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

TScan Therapeutics (TCRX) Competitors

$0.77 -0.03 (-3.67%)

As of 04:00 PM Eastern

Compare

TCRX vs. NBP, PRQR, PLX, DTIL, and VYGR

Should you buy TScan Therapeutics stock or one of its competitors? TScan Therapeutics's main competitors and comparable companies include I-Mab (NBP), ProQR Therapeutics (PRQR), Protalix BioTherapeutics (PLX), Precision BioSciences (DTIL), and Voyager Therapeutics (VYGR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TScan Therapeutics compare to I-Mab?

I-Mab (NASDAQ:NBP) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

I-Mab has higher earnings, but lower revenue than TScan Therapeutics. I-Mab is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	52.62	-$46.27M	-$0.36	N/A
TScan Therapeutics	$10.32M	4.86	-$129.77M	-$0.96	N/A

I-Mab has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. I-Mab's return on equity of 0.00% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

38.4% of I-Mab shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

I-Mab has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

In the previous week, TScan Therapeutics had 1 more articles in the media than I-Mab. MarketBeat recorded 1 mentions for TScan Therapeutics and 0 mentions for I-Mab. I-Mab's average media sentiment score of 0.00 equaled TScan Therapeutics'average media sentiment score.

Company	Overall Sentiment
I-Mab	Neutral
TScan Therapeutics	Neutral

I-Mab presently has a consensus target price of $9.00, indicating a potential upside of 408.47%. TScan Therapeutics has a consensus target price of $6.00, indicating a potential upside of 682.27%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than I-Mab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

I-Mab beats TScan Therapeutics on 8 of the 15 factors compared between the two stocks.

How does TScan Therapeutics compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

In the previous week, ProQR Therapeutics had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for ProQR Therapeutics and 1 mentions for TScan Therapeutics. ProQR Therapeutics' average media sentiment score of 0.51 beat TScan Therapeutics' score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ProQR Therapeutics currently has a consensus price target of $7.33, indicating a potential upside of 305.16%. TScan Therapeutics has a consensus price target of $6.00, indicating a potential upside of 682.27%. Given TScan Therapeutics' higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

ProQR Therapeutics has higher revenue and earnings than TScan Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.60	-$47.73M	-$0.50	N/A
TScan Therapeutics	$10.32M	4.86	-$129.77M	-$0.96	N/A

ProQR Therapeutics has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ProQR Therapeutics has a net margin of -331.33% compared to TScan Therapeutics' net margin of -1,360.61%. ProQR Therapeutics' return on equity of -84.87% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Summary

ProQR Therapeutics beats TScan Therapeutics on 12 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

In the previous week, Protalix BioTherapeutics and Protalix BioTherapeutics both had 1 articles in the media. Protalix BioTherapeutics' average media sentiment score of 1.49 beat TScan Therapeutics' score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protalix BioTherapeutics presently has a consensus price target of $12.00, indicating a potential upside of 383.87%. TScan Therapeutics has a consensus price target of $6.00, indicating a potential upside of 682.27%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Protalix BioTherapeutics has higher revenue and earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.62	$8.31M	$0.18	13.78
TScan Therapeutics	$10.32M	4.86	-$129.77M	-$0.96	N/A

Protalix BioTherapeutics has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

Protalix BioTherapeutics has a net margin of -21.03% compared to TScan Therapeutics' net margin of -1,360.61%. Protalix BioTherapeutics' return on equity of -30.89% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Summary

Protalix BioTherapeutics beats TScan Therapeutics on 9 of the 15 factors compared between the two stocks.

How does TScan Therapeutics compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Precision BioSciences has a net margin of -96.73% compared to TScan Therapeutics' net margin of -1,360.61%. Precision BioSciences' return on equity of -72.52% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Precision BioSciences presently has a consensus target price of $32.25, suggesting a potential upside of 332.31%. TScan Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 682.27%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Precision BioSciences had 18 more articles in the media than TScan Therapeutics. MarketBeat recorded 19 mentions for Precision BioSciences and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 0.00 beat Precision BioSciences' score of -0.16 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precision BioSciences has higher revenue and earnings than TScan Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	6.01	-$45.72M	-$2.80	N/A
TScan Therapeutics	$10.32M	4.86	-$129.77M	-$0.96	N/A

Precision BioSciences has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Summary

Precision BioSciences beats TScan Therapeutics on 10 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Voyager Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

TScan Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Voyager Therapeutics has a net margin of -312.63% compared to TScan Therapeutics' net margin of -1,360.61%. Voyager Therapeutics' return on equity of -54.82% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Voyager Therapeutics	-312.63%	-54.82%	-42.53%

TScan Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 682.27%. Voyager Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 420.50%. Given TScan Therapeutics' higher probable upside, research analysts plainly believe TScan Therapeutics is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Voyager Therapeutics had 6 more articles in the media than TScan Therapeutics. MarketBeat recorded 7 mentions for Voyager Therapeutics and 1 mentions for TScan Therapeutics. Voyager Therapeutics' average media sentiment score of 0.14 beat TScan Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Voyager Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Voyager Therapeutics has higher revenue and earnings than TScan Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	4.86	-$129.77M	-$0.96	N/A
Voyager Therapeutics	$40.37M	4.74	-$119.72M	-$1.80	N/A

Summary

Voyager Therapeutics beats TScan Therapeutics on 11 of the 17 factors compared between the two stocks.

Get TScan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TCRX vs. The Competition

Export

Metric	TScan Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$50.12M	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.80	9.13	269.75	24.74
Price / Sales	4.86	1,274.20	652.34	108.60
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.36	17.66	11.27	6.42
Net Income	-$129.77M	-$13.25M	$3.45B	$347.12M
7 Day Performance	6.03%	5.36%	3.56%	2.48%
1 Month Performance	-29.63%	-1.74%	-0.58%	-1.04%
1 Year Performance	-53.23%	61.36%	77.52%	23.22%

TScan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TCRX TScan Therapeutics	2.5034 of 5 stars	$0.77 -3.7%	$6.00 +682.3%	-51.5%	$50.12M	$10.32M	N/A	100	News Coverage Upcoming Earnings
NBP I-Mab	1.9882 of 5 stars	$1.66 +2.8%	$9.00 +443.8%	N/A	$191.40M	$3.89M	N/A	380
PRQR ProQR Therapeutics	3.981 of 5 stars	$1.79 +4.4%	$7.33 +310.8%	-13.6%	$189.12M	$17.99M	N/A	180
PLX Protalix BioTherapeutics	3.2333 of 5 stars	$2.34 +0.6%	$12.00 +413.9%	+59.7%	$188.14M	$76.38M	N/A	200
DTIL Precision BioSciences	2.344 of 5 stars	$7.22 +2.3%	$32.25 +346.7%	+71.0%	$186.28M	$34.26M	N/A	200	Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TCRX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TScan Therapeutics (TCRX) Competitors

TCRX vs. NBP, PRQR, PLX, DTIL, and VYGR

How does TScan Therapeutics compare to I-Mab?

Summary

How does TScan Therapeutics compare to ProQR Therapeutics?

Summary

How does TScan Therapeutics compare to Protalix BioTherapeutics?

Summary

How does TScan Therapeutics compare to Precision BioSciences?

Summary

How does TScan Therapeutics compare to Voyager Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TScan Therapeutics (TCRX) Competitors

TCRX vs. NBP, PRQR, PLX, DTIL, and VYGR

How does TScan Therapeutics compare to I-Mab?

Which has preferable earnings & valuation, NBP or TCRX?

Is NBP or TCRX more profitable?

Do insiders & institutionals believe in NBP or TCRX?

Which has more risk & volatility, NBP or TCRX?

Does the media favor NBP or TCRX?

Do analysts prefer NBP or TCRX?

Summary

How does TScan Therapeutics compare to ProQR Therapeutics?

Does the media prefer PRQR or TCRX?

Do analysts recommend PRQR or TCRX?

Which has better earnings and valuation, PRQR or TCRX?

Which has more risk & volatility, PRQR or TCRX?

Do insiders and institutionals have more ownership in PRQR or TCRX?

Is PRQR or TCRX more profitable?

Summary

How does TScan Therapeutics compare to Protalix BioTherapeutics?

Does the media prefer PLX or TCRX?

Do analysts recommend PLX or TCRX?

Do insiders & institutionals believe in PLX or TCRX?

Which has better earnings and valuation, PLX or TCRX?

Which has more volatility and risk, PLX or TCRX?

Is PLX or TCRX more profitable?

Summary

How does TScan Therapeutics compare to Precision BioSciences?

Is DTIL or TCRX more profitable?

Do analysts prefer DTIL or TCRX?

Do institutionals and insiders have more ownership in DTIL or TCRX?

Does the media refer more to DTIL or TCRX?

Which has stronger earnings and valuation, DTIL or TCRX?

Which has more risk and volatility, DTIL or TCRX?

Summary

How does TScan Therapeutics compare to Voyager Therapeutics?

Which has more risk and volatility, TCRX or VYGR?

Do institutionals & insiders hold more shares of TCRX or VYGR?

Is TCRX or VYGR more profitable?

Do analysts rate TCRX or VYGR?

Does the media prefer TCRX or VYGR?

Which has preferable valuation & earnings, TCRX or VYGR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools